Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.

SGLT-2 inhibitors cut risk of hospitalization for HF, death in real-world study

Elvira Manzano
05 Apr 2017
Dr Mikhail Kosiborod

Treatment with sodium- glucose cotransporter 2 (SGLT-2) inhibitors reduces the risk of hospitalization for heart failure (hHF) and death compared with other glucose-lowering drugs, the retrospective, observational CVD-REAL* study has shown.

Overall, there were 734 new hHF cases (incidence rate 0.41/100 person years). New users of SGLT-2 inhibitors (dapagliflozin, canagliflozin and empagliflozin) had a 39 percent lower rate of incident hHF vs new users of other glucose-lowering drugs (pooled hazard ratio [HR, 0.61; p<0.001). Similarly, rate of death from any cause (HR, 0.49; p<0.001) was lower with the SGLT-2 inhibitors as was the composite endpoint of hHF and death from any cause (HR, 0.54; p<0.001). [ACC.17, abstract 415-14]

The cardiovascular benefits appeared to be class-related than compound-specific, said lead investigator Dr Mikhail Kosiborod from the University of Missouri-Kansas City School of Medicine, Kansas City, US.

 “There was no significant heterogeneity across countries despite geographic variations in use of SGLT-2 inhibitors [canagliflozin was predominantly used in the US, dapagliflozin in Europe],” he said. “This was in a broad population of patients in general practice with type 2 diabetes [T2D], the overwhelming majority of whom did not have known cardiovascular disease [CVD].”

The researchers compared the risk of hHF, all-cause death, and the composite of hHF and death in over 300,000 patients with T2D who were newly prescribed SGLT-2 inhibitors (n=154,523) or other glucose-lowering drugs (n=154,523). Data from large registries of patients across six countries (US, Germany, Sweden, Norway, Denmark, and the UK) were pooled and analysed.

Nonparsimonious propensity scores for initiation of SGLT-2 inhibitors were used to match the two treatment groups. At baseline, 80 percent of the patients were receiving an antihypertensive, 67 percent were on a statin, and almost 80 percent were on metformin therapy. The mean age of the patients was 57; 44 percent were women.

Most patients in the US were treated with canagliflozin (75.9 percent) while almost all patients in Europe received dapagliflozin (91.9 percent). Overall, 52.7 percent of the patients were treated with canagliflozin, 41.8 with dapagliflozin, and 5.5 percent with empagliflozin.

In this large multicountry cohort, treatment with SGLT-2 inhibitors was associated with marked and highly significant reductions in HHF and death. “This is interesting as what you’re seeing in terms of HF hospitalization is primarily a heart-prevention signal rather than a heart-treatment signal,” Kosiborod said.

SGLT-2 inhibitors cut risk of hospitalization for HF, death in real-world study

“I believe this class [SGLT-2 inhibitor] has a really remarkable potential to transform how we manage diabetes and patient outcomes,” he added, suggesting that more data from multiple sources are warranted to drive the message home.

In the meantime, cardiologists await with enthusiasm the results of the ongoing CV safety studies with canagliflozin (CANVAS) and dapagliflozin (DECLARE-TIMI 58) to establish whether the benefits observed with SGLT-2 inhibitors are indeed a class-effect of the drugs.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 5 days ago

A recent study conducted by The University of Hong Kong (HKU) revealed that long-term use of proton pump inhibitors (PPIs) is associated with a significantly increased risk of gastric cancer even in patients who have had Helicobacter pylori eradicated. 

5 days ago
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
6 days ago
High levels of marijuana exposure appear to not be longitudinally associated with prevalent albuminuria and substantial changes in estimated glomerular filtration rate by cystatin C (eGFRcys), a recent US epidemiological study has shown.
4 days ago
Men with breast cancer have tumours that are typically of the human epidermal growth factor receptor 2-negative Luminal B subtype and positive for oestrogen receptor, progesterone receptor and androgen receptor, according to the results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program study.